Nine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587

Transcription

1 Media Release Basel, 3 October 20 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-2% in Swiss francs; +7% in US dollars), excluding Tamiflu Significant foreign exchange impact of -3% due to appreciation of Swiss franc; overall Group sales at 3.5 billion Swiss francs Pharmaceuticals sales excluding Tamiflu rise % (-3% in Swiss francs; +6% in US dollars) and Diagnostics sales 6% (-8% in Swiss francs; +% in US dollars) Major drivers are Roche s leading cancer medicines Herceptin (+8%) and MabThera/Rituxan (+7%), eye medication Lucentis (+26%), rheumatoid arthritis medicine Actemra (+86%) and Professional Diagnostics business (+9%) Successful US launch of targeted skin cancer medication Zelboraf and companion diagnostic cobas BRAF Mutation Test following FDA approvals in August; EU approval expected in Q 202. EU expert panel recommends approval of Avastin as front-line therapy for ovarian cancer Positive results from 7 phase III registration studies in first 9 months, including new data in July for targeted breast cancer medicine pertuzumab Full-year outlook for 20 confirmed Sales in millions of CHF Nine months ended 30 September % change At CER* In CHF In USD Pharmaceuticals Division 24,397 24,096 28,395 27, United States 9,04 8,934 0,878 0, Western Europe 6,20 6,89 7,295 7, Japan 2,72 2,643 3,37 2, International** 6,37 6,330 7,085 6, Diagnostics Division 7,095 7, Roche Group 3,492 3,9 36,27 35, * Constant exchange rates versus YTD Sept. 200; **Asia Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Canada, Others Constant exchange rates (see footnote on p.2). F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Group Communications Roche Group Media Relations Tel Fax /9

2 Commenting on the Group s 20 performance to date, Roche CEO Severin Schwan said: Roche s solid sales performance in the third quarter is in line with our expectations. We re on track to achieve our targets for 20. The successful US launch of our new melanoma medicine Zelboraf and the diagnostic cobas BRAF test has strengthened our leading position in personalised healthcare. The good results we have achieved with new medicines in seven late-stage clinical trials so far this year further enhance our prospects for future growth. Solid growth in first nine months In the first nine months of 20 Group sales at constant exchange rates 2 increased by 2% (-2% in Swiss francs, +7% in US dollars); this is excluding Tamiflu sales, which as expected were significantly lower than in the previous year. Group sales overall were stable (-3% in Swiss francs; +6% in US dollars) at 3.5 billion Swiss francs. Sales performance in both the Pharmaceuticals and the Diagnostics Division reflects the strength of the Group s business, as well as the impact of the strong appreciation of the Swiss franc against all currencies relevant for Roche. Seven positive registration studies In the first nine months of 20 Roche reported positive data from seven clinical studies, several of which have already formed the basis for regulatory filings and approvals in the third quarter (see page 0 for details on the R&D pipeline and regulatory milestones): Zelboraf for metastatic melanoma and companion diagnostic cobas BRAF Mutation Test approved and launched in the US (approval based on BRIM2 and BRIM3 studies) Tarceva approved in the EU for EGFR-mutated non-small cell lung cancer(based on EURTAC study) vismodegib filed in the US for treatment of basal cell carcinoma (supported by ERIVANCE study). primary objective achieved in phase III registration study with pertuzumab for HER2-positive metastatic breast cancer (CLEOPATRA) Growth in sales of key medicines led by Latin America and Asia Pacific Sales by the Pharmaceuticals Division, excluding Tamiflu, grew % in the first nine months of 20. Including Tamiflu, sales declined by % at constant exchange rates (-4% in Swiss francs; +4% in US dollars) to 24.4 billion Swiss francs. Sales reflected solid growth of most key medicines, including recently launched products. Negative impacts included expected decreases in sales of Avastin (due to uncertainty around the metastatic breast cancer indication in the US), Tamiflu, Bonviva/Boniva and CellCept, and sustained 2 The percentage changes at constant exchange rates (CER) are calculated using simulations by reconsolidating both the 20 and 200 results at constant currencies (the average rates for the year ended 3 December 200). This is the same concept that Roche previously labelled local currencies. 2/9

3 competitive pressure on the NeoRecormon/Epogin franchise. In the regions, growth of % in US pharmaceutical sales was driven mainly by demand for Lucentis, Rituxan and Actemra. Sales in Western Europe decreased by 4%, primarily due to government austerity measures., sales in the International region grew 6%, helped by increasing demand for key products in certain Latin American and Asia Pacific countries, notably China (+28%), Venezuela (+88%) and Brazil (+6%). A decrease of 2% in sales in Japan, excluding Tamiflu, was due primarily to ongoing effects following the disastrous earthquake in March. Diagnostics business continues to outpace the market Diagnostics Division sales continued to grow faster than the global in vitro diagnostics market, advancing 6% at constant exchange rates (-8% in Swiss francs, +% in US dollars). Growth was led by Professional Diagnostics (+9%), fuelled by continued strong growth in immunoassays and solid instrument placements, and by Tissue Diagnostics (+5%). Sales grew in all regions, with the largest gains in Asia Pacific (+7%). These reflect the strong overall demand for immunoassays and in particular the division s performance in China, where sales increased 25%. In the third quarter Roche Diagnostics launched 7 new products in key markets (see table on page ). Roche Group again recognised as global sustainability leader in healthcare In September Roche was named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for the third year in a row. This top ranking among the world s leading sustainability-driven healthcare companies is a reflection of Roche s commitment to its employees, communities and the environment, and positions Roche as a global leader in sustainable business practices. Full-year outlook confirmed Roche confirms its full-year outlook for 20 on the basis of the positive nine-month sales performance. Barring unforeseen events, Group and Pharmaceuticals sales (excluding Tamiflu) are expected to grow at low single-digit rates at constant exchange rates, reflecting the impact of US healthcare reforms and European austerity measures. Pharmaceuticals sales are thus expected to grow in line with the market. In 20 Diagnostics sales are again expected to grow significantly ahead of the market, driven by further rollouts of new products in all business areas. Thanks to ongoing cost savings and productivity gains, Roche is targeting Core EPS growth of around 0% at constant exchange rates for 20, in spite of a more challenging environment and the introduction of an excise tax in the United States. Roche aims to grow the dividend in line with Core EPS growth, and will at least maintain last year s dividend in Swiss francs. 3/9

4 Pharmaceuticals Herceptin, MabThera/Rituxan, Lucentis and Actemra lead sales growth Top-selling pharmaceuticals and recent launches Jan. Sept. 20 Total US Western Europe Japan International** CHF m %* CHF m %* CHF m %* CHF m %* CHF m %* MabThera/Rituxan 4,47 7 2,024 6, ,034 0 Avastin 3,942-8,774-5, Herceptin 3,905 8,056 5, ,82 9 Lucentis,28 26,28 26 Pegasys, Xeloda, Tarceva CellCept NeoRecormon/ Epogin Bonviva/Boniva Recent launches Actemra/RoActemra Mircera Zelboraf * At constant exchange rates versus YTD September 200 **Asia Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Canada, others Sales performance of key pharmaceutical products MabThera/Rituxan, for non-hodgkin s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA): Sustained growth in the oncology segment was driven by continued strong uptake of the new first-line maintenance indication in follicular lymphoma (a type of NHL) in Europe and the US, and by further uptake in CLL. Growth in the International region, including gains in key emerging markets, was driven by uptake in NHL indications. Growth in the RA segment is being fuelled by increased use in patients with an inadequate response to tumour necrosis factor inhibitors and shortened repeat treatment intervals. Herceptin, for HER2-positive breast cancer and HER2-positive metastatic (advanced) stomach cancer: Sustained double-digit sales increases were recorded in the International region, especially Latin America and Asia Pacific, with single-digit growth in the US, Western Europe and Japan. Sales are being driven by expanded access in developing countries, increased HER2 testing and continued uptake in HER2- positive gastric cancer. Lucentis, for wet age-related macular degeneration (AMD) and macular edema following retinal vein 4/9

5 occlusion (RVO): US sales continue to grow strongly, driven by growth of the AMD market and the new RVO indication. Publication of one-year results from the Comparisons of Age-related macular degeneration Treatments Trial (CATT), which compared Lucentis with off-label Avastin in patients with wet AMD, has had a limited impact on US sales growth. Actemra/RoActemra, for rheumatoid arthritis and systemic juvenile idiopathic arthritis: Continued uptake was seen in all approved indications. The US, where Actemra continues to gain market share, remains the largest source of growth, with strong contributions also coming from Western Europe, Japan and Latin America. Marketing and reimbursement approvals in additional countries continue to expand patient access to Actemra/RoActemra. Avastin, for advanced colorectal, breast, lung and kidney cancer, and for relapsed glioblastoma (a type of brain tumour): The expected decline in US sales was mainly due to regulatory and reimbursement uncertainty regarding the metastatic breast cancer indication. Market penetration of Avastin in lung cancer grew slightly and remained stable for all other indications. Lower sales in Europe reflect austerity measures affecting all products and lower use in breast cancer. Good growth in the International region (+9%) reflects strong uptake of Avastin in its colorectal cancer indications, including very good market uptake in China since the medicine s launch there last October. Pegasys, for hepatitis B and C: While nine-month sales declined 5% overall, renewed sales growth was recorded in the third quarter in the US (+5% vs Q3 200), where two new direct-acting hepatitis C medicines were launched in mid-20. The new medicines are designed to be given with a pegylated interferon and ribavirin (a regimen known as triple combination therapy). As the leading pegylated interferon medication, Pegasys is well positioned to be the foundation for triple combination therapy. In Europe and elsewhere patients with hepatitis C are still delaying the start of treatment in anticipation of the availability of triple combination therapy. Under a strategic agreement, Roche and Merck & Co. have initiated the first of a series of clinical trials to examine novel combinations of marketed and investigational medicines for chronic hepatitis C. In addition, a phase II study (DYNAMO ) evaluating the combination of mericitabine, Merck s Victrelis, Pegasys and ribavirin in patients who have not responded to prior therapy, is scheduled to begin shortly. 5/9

6 Diagnostics strong growth in immunoassays and advanced tissue staining Sales January September 20 In millions of CHF % change in CHF % change at CER* As % of sales Diagnostics Division 7, Professional Diagnostics 3, Diabetes Care, Molecular Diagnostics Applied Science Tissue Diagnostics Sales by region - Europe, Middle East and Africa 3, North America, Asia Pacific Latin America Japan * Constant exchange rates versus YTD September 200 Major sales drivers by business area Professional Diagnostics: Sales were driven by strong, above-market growth in immunoassays (+3%) and clinical chemistry (+6%), the unit s largest businesses, and in coagulation monitoring (+4%). Diabetes Care: Sales were driven by the new generation of Accu-Chek blood glucose (bg) meters and Accu-Chek Combo, a combined insulin pump and bg meter. The FDA s approval of the Accu-Chek Aviva Plus test strip with maltose-independent chemistry marked the first step in bringing this portfolio to the US market. The test strips were also approved in Japan for the Accu-Chek Aviva and Accu-Chek Compact. Molecular Diagnostics: Roche s HIV and HBV viral load tests (+3%) remained the main sales drivers. Uptake of the HPV test was positive; Roche won a key tender to screen women for cervical cancer in Sweden, the first country in Europe to pilot HPV first-line testing. Roche also signed a contract with LabCorp to make the recently approved BRAF melanoma test available for patient testing in the US. Applied Science: Sales continued to be impacted by the year-on-year decline in HN influenza testing, increasing competition in gene sequencing, and flat research funding. The Custom Biotech business, which offers specialty biochemicals for industrial use, continued its healthy growth (+ 2%). Tissue Diagnostics: Growth substantially ahead of the market was again driven by the advanced tissue staining portfolio (+5%). Roche completed its acquisition of mtm laboratories, including mtm s proprietary antibodies for cervical cancer detection. Tissue Diagnostics continued to launch new antibodies, bringing the total for the first nine months to 25. 6/9

7 Product pipeline focus on personalised healthcare delivering results In the third quarter, two Roche medicines and two diagnostic tests were approved for targeted cancer therapy, demonstrating that Roche is delivering on its personalised healthcare strategy: Zelboraf (vemurafenib) for the treatment of inoperable or metastatic melanoma approved in the US (August), cobas BRAF Mutation Test, to identify patients eligible for treatment with Zelboraf, approved in the US and received CE mark 3 (August) Tarceva (erlotinib) as first-line therapy for patients with a distinct form of non-small cell lung cancer (NSCLC with epidermal growth factor receptor-activating mutations) approved in the EU (August) KRAS Mutation Test for use in patients with colorectal cancer to predict non-response to certain antibody therapies received CE mark (July) In addition, the Group passed further important regulatory milestones with existing and investigational medicines. In September the Japanese authorities approved Avastin for the treatment of inoperable or recurrent breast cancer, while the EU s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Avastin as front-line therapy for ovarian cancer. Roche filed an additional EU marketing application in August seeking approval of Avastin for use in relapsed ovarian cancer and plans to file a marketing application for this indication in the US in the first quarter of 202. Also in September, Genentech filed a US marketing application for vismodegib (RG366) for the treatment of advanced basal cell carcinoma. Positive clinical trial results for key investigational new medicines In the third quarter a phase III registration study with the investigational medicine pertuzumab in HER2- positive breast cancer (CLEOPATRA) achieved its primary objective, and promising phase II proof-ofconcept data (TDM4450g) for the HER2-positive breast cancer therapy trastuzumab emtansine (T-DM) were presented at the European Multidisciplinary Cancer Congress in September. Positive results from a phase II proof-of-concept study with the asthma compound lebrikizumab (MILLY) were presented at the European Respiratory Society Congress, also in September. The lebrikizumab data were also published in a major US medical journal; phase III testing of the compound is planned to start in early 202. The third quarter also saw clinical data read-outs from programs designed to develop key marketed medicines in new indications or dosage forms. In July Chugai announced positive results from a phase III trial with a new subcutaneous formulation of Actemra in patients with rheumatoid arthritis, showing noninferiority of efficacy of the new formulation compared with the current intravenous formulation. In 3 Certification that an in vitro diagnostic product complies with all requirements for use in the European Union. 7/9

8 September Roche reported positive phase III results for Avastin in combination with pemetrexed chemotherapy as maintenance treatment in advanced non-squamous non-small cell lung cancer (AVAPERL). In early October AVEREL, a phase III study evaluating the addition of Avastin to Herceptin and chemotherapy for women with locally recurrent or metastatic HER2-positive breast cancer, did not achieve statistical significance in improving progression-free survival (PFS), as assessed by study investigators. An Independent Review Committee assessment of PFS was significant but is unlikely to be sufficient to meet regulatory approval requirements. Roche has investigational medicines for this aggressive disease in late-stage development, including pertuzumab and T DM (see above). Pharmaceuticals clinical development portfolio (phases I to III and registration) as at 30 September 20: 73 new molecular entities and 4 additional indications In the third quarter of 20 seven projects entered phase I, two entered phase II and three entered phase III One phase II project and one phase III project (Actemra/RoActemra in ankylosing spondylitis) were discontinued in the third quarter Full details of the Group s pharmaceutical R&D pipeline are available at About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 200, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D (core basis). The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: All trademarks used or mentioned in this release are protected by law. 8/9

9 Additional information - Media release including a full set of tables: - Half Year Report 20: - Roche Pharmaceuticals pipeline: - Roche Finance Info System: rofis.roche.com/dynasight/rofis.html Roche Group Media Relations Phone: / basel.mediaoffice@roche.com - Alexander Klauser (Head) - Silvia Dobry - Daniel Grotzky - Claudia Schmitt Disclaimer: Cautionary statement regarding forward-looking statements This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: () pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (0) loss of key executives or other employees; and () adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche. 9/9

10 . Pharmaceuticals Division major clinical trials in Q3 20 Product Indication Trial (phase) Outcome Aim Actemra (Japan) Avastin + Herceptin dalcetrapib dalcetrapib Lucentis rheumatoid arthritis HER2-positive metastatic breast cancer patients with coronary heart disease (CHD), or CHD risk equivalents patients with coronary heart disease (CHD), or CHD risk equivalents wet age-related macular degeneration, comparing alternative dosing regimens with monthly Lucentis double-blind, randomised, parallel group study (III) non-inferiority of efficacy of subcutaneous formulation versus intravenous formulation AVEREL (III) study did not meet protocol-specified primary endpoint dal-plaque (IIb) dal-vessel (IIb) HARBOR (III) data suggest possible beneficial vascular effects, generally well tolerated. endothelial function preserved, no change in blood pressure, generally well tolerated efficacy data do not support initiation of further clinical highdose studies, 0.5 mg PRN dosing to be discussed with FDA registration, new dosage form registration, new indication exploratory (safety, efficacy) exploratory (safety, efficacy) registration (new dosing regimen) pertuzumab HER2-positive metastatic breast cancer, combination with Herceptin and docetaxel CLEOPATRA (III) significantly improved progression-free survival registration 0/9

11 2. Pharmaceuticals Division Major regulatory approvals in Q3 20 Product Clinical data supporting filing Indication or dosage form Country Avastin International phase III data, Japanese phase II data inoperable or recurrent breast cancer, firstline treatment RoActemra TENDER systemic juvenile idiopathic arthritis EU Japan Pegasys Japanese phase II/III data chronic hepatitis B Japan Pegasys 4 clinical studies Pegasys ProClick Disposable Auto Injector EU, US Tarceva EURTAC, published clinical experience metastatic non-small cell lung cancer with epidermal growth factor receptor-activating mutations, first-line treatment Tarceva PA 3, Japanese phase II data pancreatic cancer not amenable to curative resection, combination with gemcitabine Zelboraf BRIM2, BRIM3 BRAF V600E mutation-positive inoperable or metastatic melanoma, as determined by an FDA-approved test EU Japan USA 3. Pharmaceuticals Division Major regulatory filings in Q3 20 Product Clinical data supporting filing Indication Avastin OCEANS (AVF4095) ovarian cancer, relapsed EU Tarceva EURTAC metastatic non-small cell lung cancer with epidermal growth factor receptor-activating mutations, first-line treatment vismodegib ERIVANCE BCC (SHH4476G) advanced basal cell carcinoma where surgery is considered inappropriate Country Switzerland USA 4. Diagnostics Division Major launches in Q3 20 Business area Product Market Month Professional cobas c 702: clinical chemistry module for high-volume laboratories US July Diagnostics (throughput: 2,000 tests/hour), part of the cobas 8000 modular analyser series PTH (-84) immunoassay: monitoring of parathyroid hormone levels in patients with chronic kidney disease, to help physicians better manage bone metabolism disorders EU July Molecular Diagnostics Two tests for personalised cancer treatment: - BRAF V600 Mutation: detects a BRAF gene mutation in melanoma tumours, to identify patients eligible for treatment with Zelboraf EU, US August /9

12 - KRAS Mutation: detects mutations of the KRAS gene in colorectal cancer tumours, to help guide therapy selection EU July Applied Science Cedex Bio: bioprocess analyser for biotherapeutics manufacturing, measures 4 different parameters WW Sept. Tissue Diagnostics Eleven immunohistochemistry (IHC) assays including: - anti-h. pylori: first FDA-cleared antibody to detect helicobacter pylori, a precursor to gastritis and ulcers - anti-mlh-: supports the diagnosis of colorectal cancer - anti-bcl-2: helps identify follicular and large cell lymphomas US WW WW Sept. July Sept. Ultimate Reagent Access: expedited slide tissue processing, enabling greater throughput and reduced test time in the laboratory EU, APAC, LATAM Sept. APAC = Asia Pacific, EU = European Union, LATAM = Latin America, US = United States, WW = worldwide 5. Quarterly sales by Division in 200 and 20, including/excluding Tamiflu CHF millions Q3 200 Q4 200 Q 20 Q2 20 Q3 20 Pharmaceuticals Division United States Western Europe Japan International* 9,009 8,9 3,506 3,504 2,25 2,25,076,030 8,663 8,598 3,93 3,53 2,72 2,73,82,54 8,72 8,460 3,322 3,48 2,209 2, ,03 8,093 2,963 2,959 2,090 2, ,582 7,543 2,89 2,827,9,899 2,76 2,6 2,278 2,22,97 2,26 2,8 2,256 2,20,954 Diagnostics Division 2,482 2,683 2,408 2,448 2,239 Roche Group,49,393,346,28,20 0,868 0,55 0,54 *Asia Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Canada, Others ,82 9,782 2/9

13 6. Quarterly constant exchange rate sales growth by Division in 200 and 20, including/excluding Tamiflu Pharmaceuticals Division United States Western Europe Japan International* Q4 200 Q Q 20 Q Q2 20 Q Q3 20 Q Diagnostics Division Roche Group *Asia Pacific, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Canada, Others /9

14 7. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD Sep 20 YTD Sep 200: US, Western Europe, Japan and International Total United States Western Europe Japan International CHF m % CHF m % CHF m % CHF m % CHF m % MabThera/Rituxan 4,47 7% 2,024 6%,82 6% 77 0%,034 0% Avastin 3,942-8%,774-5%,092-0% 438 9% 638 9% Herceptin 3,905 8%,056 5%,463 3% 204 2%,82 9% Lucentis,28 26%,28 26% Pegasys,05-5% 222 -% 227-5% 69-5% 533-2% Xeloda,00 6% 377 2% 20-2% 80-6% 343 7% Tarceva 92 6% 347 6% 283-3% 64 6% % CellCept 770-2% 58-3% % 45 3% 347 0% NeoRecormon/Epogin % % % 204-3% Bonviva/Boniva 55-9% % 70-4% % Xolair 446 0% 446 0% Actemra/RoActemra % % 43 66% 32 29% 60 27% Valcyte/Cymevene 425 9% 92 2% 20 6% % Pulmozyme 358 9% 208 2% 76 4% % Activase/TNKase 33 5% 300 6% % Tamiflu 30-57% 70 2% 2 625% 69-60% 4-89% Nutropin 242-6% 235-5% % Mircera % % % Madopar 222 8% % 6 3% 36 3% Neutrogin 200-3% % - - 4/9

15 8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Q3 200 Q3 200 Q Q4 200 Q4 200 Q Q 20 Q 20 Q 200 Q2 20 Q2 20 Q2 200 Q3 20 Q3 20 Q3 200 MabThera/Rituxan,520 6%,535 0%,556 7%,500 6%,36 7% Avastin,608 7%,460 2%,47-6%,309-9%,26-0% Herceptin,357 8%,266 5%,386 8%,330 2%,89 4% Lucentis % % % % 359 7% Pegasys 384-8% 392 9% 346-5% 349-7% 356 6% Xeloda 36 6% 333 4% 342 7% 326 2% 333 0% Tarceva 33 9% 320 0% 37 8% 297 % 307 0% CellCept 299-4% 289 5% 280-4% 258-3% 232-9% NeoRecormon/Epogin 32-6% 296-8% % 247-8% 97-28% Bonviva/Boniva 246 2% 223-3% 22-5% 82-9% 57-24% Xolair 67 0% 50 5% 49 3% 5 9% 46 9% Actemra/RoActemra 07 76% 35 58% 29 % 48 90% 56 69% Valcyte/Cymevene 57 % 52 4% 45 8% 37 0% 43 8% Pulmozyme 2 2% 28 5% 3 8% 6 9% % Activase/TNKase 9 5% 4-3% 22 23% 09 8% 00 5% Tamiflu 98-90% 65-94% % 0-88% 39-5% Nutropin 7 9% 95 % 87 8% 82 % 73-2% Mircera 6 37% 70 37% 70 30% 68 2% 99 82% Madopar 77 % 77 7% 75 8% 75 7% 72 8% Neutrogin 82-23% 82-8% 6-24% 74-4% 65 -% 5/9

16 9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States Q3 200 Q3 200 Q Q4 200 Q4 200 Q Q 20 Q 20 Q 200 Q2 20 Q2 20 Q2 200 Q3 20 Q3 20 Q3 200 MabThera/Rituxan 729 2% 72 6% 73 5% 690 7% 62 7% Avastin 802-3% 656-0% 648-4% 590-5% 536-6% Herceptin 398 4% 367 7% 374 3% 352 7% 330 4% Lucentis % % % % 359 7% Pegasys 92-2% 89 6% 65-28% 70-7% 87 5% Xeloda 36 8% 24 0% 23 3% 9 2% 35 23% Tarceva 38 3% 27-6% 8 0% 0 % 9 7% CellCept 62-47% 54 40% 54-27% 52-2% 52 2% NeoRecormon/Epogin Bonviva/Boniva 32 2% 0-2% 04-9% 75-3% 67-36% Xolair 67 0% 50 5% 49 3% 5 9% 46 9% Actemra/RoActemra % % 37 53% Valcyte/Cymevene 86 3% 74 8% 68 8% 59 3% 65-4% Pulmozyme 73 -% 76 2% 75 % 66 % 67 4% Activase/TNKase 09 6% 0-3% 24% 99 20% 90 5% Tamiflu 2-97% 40-89% 74 5% 4-56% -8 - Nutropin 4 20% 92 % 85 8% 79 % 7-2% Mircera Madopar Neutrogin /9

17 0. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Western Europe Q3 200 Q3 200 Q Q4 200 Q4 200 Q Q 20 Q 20 Q 200 Q2 20 Q2 20 Q2 200 Q3 20 Q3 20 Q3 200 MabThera/Rituxan 394 5% 38 5% 4 5% 400 6% 37 8% Avastin 423 4% 393-3% 393-8% 363-2% 336-9% Herceptin 506 4% 472 % 53 % 49 5% 459 4% Lucentis Pegasys 78-4% 83 2% 87-2% 79-3% 6-0% Xeloda 73 % 73 7% 69-4% 69 -% 63 -% Tarceva 98-8% 02-5% 0-2% 9-2% 9 6% CellCept 08-2% 03-7% 83-24% 76-27% 6-35% NeoRecormon/Epogin -26% 97-30% 87-30% 8-28% 72-26% Bonviva/Boniva 68 0% 70-2% 63-0% 60-2% 47-2% Xolair Actemra/RoActemra 37 20% 39 4% 45 88% 49 67% 49 5% Valcyte/Cymevene 4 0% 4 7% 4 % 4 % 38 8% Pulmozyme 26 -% 26 % 27 % 25 6% 24 5% Activase/TNKase Tamiflu - -00% % % Nutropin Mircera 43 8% 47 20% 45 % 45 6% 43 5% Madopar 25-3% 27 4% 24-2% 23-5% 23 6% Neutrogin /9

18 . Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan Q3 200 Q3 200 Q Q4 200 Q4 200 Q Q 20 Q 20 Q 200 Q2 20 Q2 20 Q2 200 Q3 20 Q3 20 Q3 200 MabThera/Rituxan 70 8% 8 6% 57 9% 58-5% 62 -% Avastin 62 5% 87 50% 43 22% 49 7% 46 2% Herceptin 74-5% 82-0% 64-3% 90 30% 50-23% Lucentis Pegasys 3-4% 36 5% 25-2% 24-2% 20-28% Xeloda 33 64% 35 33% 27 2% 27-9% 26-9% Tarceva 24 45% 29 45% 20 22% 22 0% 22 2% CellCept 5 2% 8 25% 4 6% 5 9% 6 5% NeoRecormon/Epogin 23-0% 28 -% 85-5% 98 -% 63-42% Bonviva/Boniva Xolair Actemra/RoActemra 43 60% 55 74% 40 35% 44 27% 48 25% Valcyte/Cymevene Pulmozyme Activase/TNKase Tamiflu 46-88% 28-89% 48-6% 3-68% 8-55% Nutropin Mircera Madopar 6 2% 7 5% 5 0% 6 % 5-2% Neutrogin 82-23% 82-8% 6-24% 74-4% 65 -% 8/9

19 2. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International Q3 200 Q3 200 Q Q4 200 Q4 200 Q Q 20 Q 20 Q 200 Q2 20 Q2 20 Q2 200 Q3 20 Q3 20 Q3 200 MabThera/Rituxan 327 6% 36 25% 375 5% 352 5% 307 9% Avastin 22 34% % 233 6% 207 8% 98 5% Herceptin % 345 3% % % 350 9% Lucentis Pegasys 83-9% 84 6% 69-6% 76-3% 88 5% Xeloda 9 28% 0 2% 23 0% 5% 09 6% Tarceva 7 26% 62 0% 78 6% 74 22% 75 23% CellCept 4 8% 4 3% 29 -% 5-5% 03 5% NeoRecormon/Epogin 78-4% 7-7% 74-7% 68-3% 62-8% Bonviva/Boniva 46 6% 43-6% 45-9% 47 2% 43 7% Xolair Actemra/RoActemra 9 900% 5 458% 7 338% 2 203% 22 77% Valcyte/Cymevene 30 8% 37 3% 36 8% 37 24% 40 42% Pulmozyme 22 8% 26 22% 29 5% 25 3% 20 2% Activase/TNKase 0 2% 3 5% 3% 0 % 0 7% Tamiflu 50-70% -2-99% 22-90% 2-97% 7-62% Nutropin 3-6% 3-5% 2-5% 3-7% 2 % Mircera 8 38% 23 94% 25 86% 23 32% 25 65% Madopar 46 23% 43 9% 46 4% 46 5% 44 0% Neutrogin /9